KCNK9
Potassium channel subfamily K member 9
As of the edition of 20 October 2026, KCNK9 (potassium channel subfamily K member 9, UniProt Q9NPC2) has 7 drugs tested at it and 7 companies on the list, 0 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NPC2
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 23
- Disease areas
- Nervous system; Heart and blood vessels; Mental health; Lungs and airways; Cancer; Urinary and reproductive; Digestive system; Pregnancy and women's health
- Registered trials of its drugs
- 395
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Status not established | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sevoflurane | Marketed | Phase 4 | none listed |
| Desflurane | Marketed | Phase 4 | none listed |
| Isoflurane | Marketed | Phase 4 | none listed |
| Doxapram | Marketed | Phase 4 | none listed |
| BAY2586116 | Status not established | Phase 2 | none listed |
| Enflurane | Marketed | No phase stated | none listed |
| Halothane | Marketed | No phase stated | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 3 |
| Undetermined | 4 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| AbbVie | Route B |
| Kissei Pharmaceutical | Route B |
| Baxter Healthcare | Route B |
The other 4 companies at KCNK9
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at KCNK9, ranked, with the facts behind eachRequest access. Nothing is shown until you do.